[ad_1]
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical
company focused on discovering, developing, and commercializing
gene therapies to cure blindness diseases and developing a vaccine
to save lives from COVID-19, today announced that it has commenced
an underwritten public offering of its common stock. In addition,
Ocugen expects to grant to the underwriter a 30-day option to
purchase up to an additional 15% of shares of the common stock sold
in the public offering. All of the securities in the offering are
to be sold by Ocugen. The offering is subject to market and other
customary closing conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
Ocugen intends to use the net proceeds of the proposed offering
for general corporate purposes, capital expenditures, working
capital and general and administrative expenses
Cantor Fitzgerald & Co. is acting as the sole book-running
manager for the offering.
The offering is being made by Ocugen pursuant to a shelf
registration statement on Form S-3ASR previously filed with the
Securities and Exchange Commission (the “SEC”) on March 22, 2021,
which became automatically effective upon filing with the SEC. A
preliminary prospectus supplement related to the offering will be
filed with the SEC and will be available on the website of the SEC
at www.sec.gov. Copies of the preliminary prospectus supplement and
accompanying base prospectus relating to this offering may be
obtained, when available, from Cantor Fitzgerald & Co., Attn:
Capital Markets, 499 Park Avenue, 4th floor, New York, NY 10022;
Email: prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction.
About Ocugen, Inc.
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused
on discovering, developing, and commercializing gene therapies to
cure blindness diseases and developing a vaccine to save lives from
COVID-19. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema and
diabetic retinopathy. We are co-developing Bharat Biotech’s
COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian
markets.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, which are subject to risks and uncertainties. Such
forward-looking statements within this press release include,
without limitation, statements regarding market conditions, the
completion of the proposed offering, the satisfaction of customary
closing conditions related to the proposed offering and the
intended use of net proceeds from the proposed offering. There can
be no assurance that we will be able to complete the proposed
public offering on the anticipated terms, or at all. We may, in
some cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from our
current expectations, such as market and other conditions. These
and other risks and uncertainties are more fully described in our
periodic filings with the SEC, including the risk factors described
in the section entitled “Risk Factors” in the quarterly and annual
reports that we file with the SEC. Any forward-looking statements
that we make in this press release speak only as of the date of
this press release. Except as required by law, we assume no
obligation to update forward-looking statements contained in this
press release whether as a result of new information, future events
or otherwise, after the date of this press release.
Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com
Historical Stock Chart
From Jan 2022 to Feb 2022
Historical Stock Chart
From Feb 2021 to Feb 2022
[ad_2]
Source link
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Jessica Wilson
- Jessica Wilson
- Subash Kafle
